ABOUT US

NEWS

INVESTOR RELATIONS

简 繁 EN
Essex-Bio Group
简 繁 EN
简 繁 EN
COMPANY NEWS
Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore
2023.04.14
Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC® Absorbable Dressing in Mainland China
2023.04.11
Essex Bio-Technology Announces 2022 Annual Financial Results, Resilience & Relevance, Growth Ready
2023.03.08
Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration
2023.02.22
Time
Last 7 days Last 30 days The last six months
Date
Title
2023-04-14
Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore
2023-04-11
Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC® Absorbable Dressing in Mainland China
2023-03-08
Essex Bio-Technology (1061.HK) 2022 Annual Results at a glance
2023-03-08
Essex Bio-Technology Announces 2022 Annual Financial Results, Resilience & Relevance, Growth Ready
2023-02-23
2023-02-22
Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration
2023-02-10
First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases
2022-10-13
Essex Biotechnology Secures Exclusive Global Rights and Interests of SkQ1 in the field Ophthalmology from Mitotech
< 1 2 3 4 5 6 7 ... 8 
Essex-Bio Group
BIOTECH
HEALTHTECH
Links
Wuhan Adv.Dental Bio-Technology
UNO Medical Group
Antikor Biopharma
Mitotech S.A.
Henlius
Humacyte
Copyright © 2020 Essex Bio-Technology Limited All Rights Reserved.
Disclaimer | Privacy Policy
粤公网安备 44049102496184号粤ICP备09032349号-1 深圳网站建设 深圳联雅
This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.
ACCEPT